Tag Archives: announces

A leader in Intelligent Automation services Digital Workforce announces its expansion into Germany and opens two new offices

Digital Workforce, a global leader in RPA and Intelligent Automation services, announces its expansion into Germany, opens offices in Munich and Stuttgart and welcomes Jürgen Vollmer as Sales Director in DACH. Munich, January 2, 2020 – Digital Workforce, Europe’s fastest-growing automation disruptor, has been expanding into new countries in the past eight months by establishing… Read More »

Ascension announces updates to several key leadership positions

Anthony R. Tersigni, EdD, FACHE Nonprofit Catholic health system Ascension, one of the biggest in the country, has announced several key changes to its leadership. The changes will be effective on July 1. IMPACT The changes are as follows: Anthony R. Tersigni, will transition his responsibilities as Ascension CEO and will continue to serve Ascension… Read More »

BCG’s INVERTO announces new Managing Director and plans to accelerate UK growth

INVERTO, Boston Consulting Group’s procurement focused subsidiary, is expanding its UK presence as companies continue to manage growth, economic uncertainty and supply chain disruption LONDON, 8 March – INVERTO, one of Europe’s leading procurement and supply chain management consultancies, and a subsidiary of Boston Consulting Group (BCG), is announcing UK expansion plans to help companies… Read More »

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Print this page ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in… Read More »

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns

Print this page DUBLIN–(BUSINESS WIRE)–Dec. 27, 2018– Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for Ravicti (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with a urea cycle disorder… Read More »